Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population. sec-Butylpropylacetamide (SPD) is a novel amide analogue of valproic acid (VPA) previously shown to possess a broad spectrum of anticonvulsant activity. In this study, we defined the pharmacokinetic parameters of SPD in rat and mouse, and then evaluated its antinociceptive potential in neuropathic and acute inflammatory pain models. In the sciatic nerve ligation (SNL) model of neuropathic pain, SPD was equipotent to gabapentin and more potent than its parent compound VPA. SPD also showed either higher or equal potency to VPA in the formalin, carrageenan, and writhing tests of inflammatory pain. SPD showed no effects on compound action potential properties in a sciatic nerve preparation, suggesting that its mechanism of action is distinct from local anesthetics and membrane stabilizing drugs. SPD's activity in both neuropathic and inflammatory pain warrants its development as a potential broad-spectrum anti-nociceptive drug.
profile and high abuse potential [2, 3] . Neuropathic pain is caused by traumatic, inflammatory, or dysmetabolic lesions to the central or peripheral nervous system [4] . Traditionally, changes in neuronal or synaptic physiology have been advanced as mechanisms of neuropathic pain [5] , however many studies indicate that the traditional focus on these factors provides an incomplete picture [6] [7] [8] [9] . Neuropathic pain is typically treated with membrane stabilizing agents (e.g. antiepileptic drugs (AEDs) or local anesthetics (e.g. lidocaine)), that aim to modulate ion channel activity [10, 11] . However, this strategy has met with limited success, suggesting the involvement of other, possibly inflammatory, mediators in chronic pain states [5, 7, 9] . Inflammatory mechanisms are known to contribute significantly to the development of chronic neuropathic pain [8, 10, 12] . That said, non-steroidal anti-inflammatory drugs (NSAIDs) have limited efficacy for neuropathic pain conditions [13] and are not included in the pain treatment guidelines [14, 15] . Opioids are indicated for both inflammatory and neuropathic pain, although their efficacy in neuropathic pain is still controversial [16] . They also carry the risk of potential tolerance and have a high addiction liability [17] . This supports the need for further development of more tolerable broad spectrum pain medications that target both the inflammatory, and neuropathic components of chronic pain. sec-Butylpropylacetamide (SPD) (Fig. 1) is a second generation amide derivative of valproic acid (VPA, Fig. 1 ), previously found to be active in numerous animal seizure models [18, 19] . Epilepsy and neuropathic pain are thought to share some aspects of their underlying pathophysiology [11] , and some AEDs are used for the treatment of neuropathic pain (e.g. gabapentin) [20, 21] . Owing to its broad-spectrum and promising effect as an anticonvulsant compound, we evaluated SPD's potential in both neuropathic and acute inflammatory pain models. In this work, we show SPD to be active in the spinal nerve ligation (SNL) model for neuropathic pain and three models of acute inflammatory pain. Compared to its parent compound VPA, SPD had higher potency in the SNL model and a higher or equivalent potency in the inflammatory pain models. Its effects suggest a different pharmacological profile than either conventional membrane stabilizers or NSAIDs. We also evaluated SPD's pharmacokinetic profile to demonstrate its favorable PK profile and to explore its pharmacokinetic (PK) -pharmacodynamic (PD) correlation. Our results support further evaluation of SPD for the treatment of refractory pain.
Materials and methods
All experiments, analysis, and reporting were performed according to the ARRIVE criteria [22] .
Animals
All acute inflammatory pain experiments were conducted using male CF-1 mice (20-30 g, Charles River Laboratories, Raleigh, NC). Neuropathic pain models were performed on male Sprague-Dawley rats (200-250 g, Harlan Laboratories, Jerusalem). Electrophysiology recordings were done in vitro on acutely dissected sciatic nerves from male Sprague Dawley rats (300-450 g). Animals were housed in clear acrylic glass cages in an Institutional Animal Care and Use Committee (IACUC) approved animal facility and were allowed free access to food (product 8640, Harlan Teklad, WI, USA) and water. All animal cages were maintained in a temperature, humidity, and 12:12 h light:dark cycle controlled environment. Every attempt was made to minimize the pain experienced by experimental animals. All experiments were approved by the University of Jerusalem and University of Utah's IACUC.
Materials used
sec-Butylpropylacetamide (SPD), N-methyl tetramethylcyclopropyl acetamide (MTMCD) used as a positive control in the SNL model, and N-methyl valnoctamide (N-methyl VCD) used as internal standard in the PK studies were synthesized according to a previously published procedure [19] .
Formalin solution, 37% v/v in water (10%-15% in methanol), glacial acetic acid, methyl cellulose (MC, 4000 Centipoise), -carrageenan, Ibuprofen sodium salt, sodium valproate and sodium pentobarbital were all purchased from Sigma-Aldrich (St.
Louis, MO, USA). Lidocaine hydrochloride was purchased from Spectrum Chemicals Mfg. Corp. (Gardena, CA, USA). Both SPD and VPA were suspended in 0.5% MC before they were injected i.p. to mice, at doses lower than their TD 50 values previously evaluated (88 mg/kg and 391 mg/kg i.p. for SPD and VPA respectively [18] ).
Spinal nerve ligation (SNL) model for neuropathic pain
Rats were evaluated twice for their tactile allodynia threshold, 1 and 2 days prior to surgery. All rats included in the experiment had pain threshold >15 g in both hind paws before surgery. The surgical procedure used to produce allodynia was previously described by Kim and Chung [23] . Briefly, rats were anesthetized following i.p. administration of 85 mg/kg ketamine and 15 mg/kg xylazine. With the rats in prone position, the paraspinal muscles on the left were carefully separated from the L4 to the S2 transverse processes, followed by removal of the L6 transverse process in order to visualize the L5-L6 spinal nerves. These were tightly ligated with a 5-0 silk thread and cut distal to the ligature. The paraspinal muscles were closed with sutures, and the skin was closed with Michel clips. A bacteriostatic powder was then applied topically, followed by intramuscular administration of ampicillin. Recovery after surgery lasted 5 days before commencement of the behavioral tests. The rat's foot withdrawal in response to tactile stimulus was used to detect tactile allodynia using a set of nine nylon von-Frey filaments (VFF). VFF produced an initial bending force of (in mN): 5.8, 13.7, 19.6, 39.2, 58.7, 78.3, 97.9, 146.9, and 254.5, equivalent to a mass of (in grams): 0.6, 1.4, 2, 4, 6, 8, 10, 15, and 26. The same set was calibrated and used in all experiments. SPD was administered intraperitoneally (i.p.) at 40, 60, and 80 mg/kg vs. negative control (MC) at 7, 14, and 21 days post-surgery using a Latin square design protocol where the experimenter who performed the behavioral tests was not aware of the dose nor substance given to the animals tested. MTMCD was used as a positive control comparator. The VFF were applied briefly, just before and 30, 60, 120, 180, and 240 min after injection at 1-2 s interval to the mid plantar skin of the hind paw. Stimulation began with the 0.6 g VFF, using a perpendicular force to the skin that was just sufficient to bend the monofilament. If the animal failed to respond with a brief paw withdrawal to at least 3 out of 5 stimuli, the next monofilament was tested using an ascending staircase protocol. The response threshold was set as the average of the minimal force required to obtain a criterion response on the two repeats. Rats were considered "protected" from allodynia if they failed to respond to the 15 g VFF (considered 100% protection).
Formalin test
Formalin test was performed according to a previously published paradigm [24, 25] . A total of ten groups, each having eight mice per group, were used in the study; a control group (MC) was paired with each of the five dose groups. Mice were placed in cylindrical clear acrylic glass chambers (6 tall × 4 diameter) for a 15 min acclimation period followed by i.p. injection of either MC or test compound. SPD and VPA were administered i.p. to mice at 35 and 70 mg/kg for SPD and 70, 100, and 300 mg/kg for VPA. Fifteen minutes after i.p. injection, (anti-seizure time to peak effect (TPE) for both SPD and VPA [18] ), 20 l of formalin solution (5% v/v solution in double-distilled water) was injected into the plantar region of each mouse's left paw. Time spent licking or biting their injected paw was measured for the first two minutes of each five minute interval over a total observation period of forty minutes following formalin injection. Two animals were observed in each trial and a total of eight animals were tested per dose. Licking time was quantified as the area under the curve (AUC) divided in two phases for analysis: the acute (0-10 min) and inflammatory (10-40 min) phases, normally seen in this test [26] . Results are reported as % control AUC for each phase. The experimenter who performed the procedure was blinded to the treatment groups.
Carrageenan test
Heat hyperalgesia was evaluated for control, SPD, and VPA treated mice 3 h following subcutaneous (s.c.) plantar injection of carrageenan using the Hargreaves test [27] . Four doses were chosen for evaluation of SPD's activity (10, 30, 50 , and 70 mg/kg; n = 14 in the 10, 30 mg/kg SPD; n = 24 in the 50, 70 mg/kg SPD). VPA was evaluated at 100 mg/kg (n = 23). Animals were acclimated to the hot plate (maintained at 30 • C) for one hour before carrageenan injection. Each mouse was injected with 25 l of carrageenan solution (20 mg/ml w/v, in saline) s.c. into the plantar area of their left hind paw and were returned to the warmed plate for an additional 2 h before evaluation of heat hyperalgesia. Two control groups were used: a negative control group in which mice received a plantar injection of saline followed by an i.p. injection of MC (Sal/MC, n = 30); a positive control group in which mice received a plantar injection of carrageenan followed by i.p. injection of MC (Carr/MC, n = 40). Fifteen minutes before evaluation of heat hyperalgesia (corresponding to their TPE [18] ), mice received an i.p. injection of either MC, SPD, or VPA and were returned to the hot plate apparatus. A light beam set to 35% intensity (Hargreaves Plantar test model 400, IITC Life Sciences, Woodland Hills, CA) was aimed at the center of the hind paw and the latency of the injected hind paw to flinch from the radiant heat source was observed and recorded. This was defined as the withdrawal latency of the measured hind paw. The flinch was often accompanied by licking of the injected hind paw. Latency to flinch was measured twice in both the injected (ipsilateral) and un-injected (contralateral) paws, and the mean of two consecutive recordings spaced 5 min apart served as a representative mean withdrawal time for each paw. In each experiment, two groups of up to eight animals per group were tested sequentially over a period of 30 min. The normalized mean withdrawal time for each treatment was calculated by subtracting the mean withdrawal latency of the un-injected paw from the mean withdrawal latency of the injected paw. One hour following commencement of testing, paw thickness for both hind paws was recorded as a measure of edema using a caliper. The experimenter was blinded to the treatment groups.
Carrageenan induced paw edema (24 h)
SPD (70 mg/kg) was evaluated for its effect on carrageenan induced paw edema vs. Ibuprofen (100 mg/kg) as a positive control [28] . Twenty male CF-1 mice (20-35 g) were used in this study, equally and randomly divided to four groups: two drug treated (SPD/Carr, Ibu/Carr) and two control groups (MC/Carr, MC/Saline). SPD and Ibuprofen vs. MC were injected i.p. two hours before intra-plantar injection of 25 l -carrageenan. A negative control group i.p. injected with MC and intraplantar injection of saline (MC/Saline) was evaluated as well. Paw thickness of both the injected and un-injected paws were recorded using a caliper over a 24 h period immediately before (baseline) and after plantar injection of either carrageenan or saline at eight time points: 0.5, 1, 2, 3, 4, 6, 8, and 24 h. Percent change in paw edema was calculated as paw thickness measured in each time point divided by baseline paw thickness.
Acetic acid-induced abdominal constriction (Writhing) test
SPD (10, 30, 50 , and 70 mg/kg) and VPA (10, 50, and 100 mg/kg) were evaluated for their ability to block acetic-acid induced abdominal constriction [29] . Eleven male CF-1 mice (20-30 g) were used in each of the groups. Before administration of either control or test substance, the mice were allowed to acclimate for 15 min in a clear acrylic glass chamber (6 tall × 4 diameter). Each of the compounds tested were mixed with 1.5 mg/ml of methylene blue in order to verify the injection site. Each mouse received an i.p. injection of either control or test compound. Fifteen minutes later, a contralateral injection of 0.6% v/v acetic acid solution in saline was injected into the peritoneal cavity at a volume of 0.1 ml for 10 g body weight, corresponding to the compound's TPE [18] . Mice were placed in the transparent round chambers and were observed for the occurrence of abdominal constriction (writhing). A writhe was defined as a contraction of the abdominal muscles accompanied by elongation of the body and extension of the hind limbs. The individual writhing response was considered terminated when the animal returned to normal posture. The number of writhes in a five minute epoch was recorded for a total of 30 min. The experimenter was blinded to the treatment group tested.
Sciatic nerve recording
Compound action potentials (CAPs) were recorded using a modified sucrose gap technique [30, 31] . Male naïve Sprague Dawley rats (300-450 g) were deeply anesthetized by 60 mg/kg, i.p. sodium pentobarbital and sacrificed by decapitation. The sciatic nerve was removed from its proximal spinal bifurcation of the L4 and L5 branches to its distal trifurcation of the tibial, sural, and common peroneal branches, while constantly maintaining a hydrated environment using HEPES buffered artificial cerebrospinal fluid (ACSF) (NaCl 130 mM, KCl 3 mM, MgCl 2 2 mM, CaCl 2 2 mM, HEPES 10 mM, d(±)-glucose 20 mM). The excised sciatic nerve was mounted on a Sylgard chamber divided by vasoline gaps and perfused with ACSF at a temperature of 20-25 • C. Low and high frequency stimulation protocols were evaluated and stimulation was provided via an A395 linear stimulus isolator (WPI, FL) using platinum/iridium wire electrodes. Recordings were made with a P55 differential A/C preamplifier (Grass Instruments, RI) with bandpass filter settings of 1 Hz and 1 kHz. Supramaximal stimulation (50 V) was delivered using a low frequency stimulation protocol (tonic stimulation: 1 ms duration, 0.2 Hz frequency) or a high frequency stimulation protocol (phasic stimulation: 0.1 ms, 40 Hz train frequency, 700 ms train duration). A 15 min baseline recording was obtained followed by a 15 min perfusion with 1 mM or 3 mM of SPD for tonic stimulations and a 25 min perfusion for phasic stimulations. All experiments were concluded by a 15 or 25 min perfusion of 1 mM lidocaine as a positive control in the tonic and phasic stimulation protocols, respectively. With the exception of 3 mM SPD, all compounds were dissolved in ACSF, 3 mM SPD was dissolved in 1% ethanol in ACSF. CAPs for the A and C fibers were determined based on the difference in their conduction velocity and stimulation thresholds. Peak to peak area ratio was calculated for the A and C fibers in the tonic stimulation protocol, and for the first and last CAPs seen in the phasic stimulation protocol for baseline and following each treatment. Percent change in amplitude between first and last CAPs in the pha-sic stimulation protocol ( f) was calculated using the following formula: f = Last CAP area ratio First CAP area ratio × 100
An average of 10 consecutive traces was calculated at the end of each treatment and was normalized to baseline for comparison. All experiments were performed at room temperatures i.e., 20-25 • C.
Pharmacokinetic (PK) study
SPD plasma concentrations vs. time were evaluated following i.p. injection of 80 mg/kg SPD to both mice and rats. SPD was suspended in 0.5% MC and i.p. injected to twenty eight mice, and twenty four rats. Four mice and four rats were used for each time point. The choice of dose was based on the maximal effective dose for SPD. Following i.p. administration of the compound, 0.5-1.0 ml blood was withdrawn from the aorta into heparinized tubes in mice, and 5 ml was withdrawn via cardiac puncture in rats, immediately following sacrifice of the animal. Blood samples were collected at 0.25, 0.5, 1, 1.5, 2, 2.5, and 4 h in mice and 0.25, 0.5, 1, 1.5, 2, and 4 h in rats after administration of the compound, and were centrifuged at 3000g for 10 min. Plasma was separated from blood and stored at −80 • C until analyzed.
Determination of median effective dose (ED 50 )
The ED 50 value was defined as the dose that produced antinociception in 50% of the animals tested. The Lichtfield & Wilcoxon II procedure was used to calculate the ED 50 value from the corresponding quantal dose-response curve [32] . The percent responders were calculated for each dose as the number of animals which displayed 50% or more change in behavior compared to control animals thereby permitting the establishment of doseresponse curves. The data was subjected to probit analysis [33] and the 95% confidence interval (CI) was calculated for both SPD and VPA.
SPD plasma concentration analysis
SPD plasma concentrations were analyzed following development of a bioanalytical assay and using gas chromatograph mass spectrometry (GC/MS). Plasma (100 l) was added to tubes containing 5 l internal standard solution (N-methyl VCD in methanol 50 g/ml). Analyte was extracted from plasma samples by adding 0.3 ml of chloroform and vigorously vortex-mixing the samples for 30s. Following brief centrifugation to separate the phases, the chloroform layer was removed and evaporated to dryness under a stream of nitrogen at ambient temperature. The sample residues were reconstituted with 0.1 ml of chloroform of which 2 l was injected into an Agilent 7000 GC/MS-MS instrument. The GC-MS was equipped with an Agilent 7693 autosampler, and a 7890A Gas Chromatograph. The column used was an Agilent J&W DB-1MS (30 m × 0.25 mm I.D. 0.1 m film thickness). Samples were injected using the pulsed splitless mode at 225 • C using Helium as a carrier gas. The oven was held at 60 • C for 1 min then heated at 30 • C/min to 200 • C followed immediately by heating to 325 • C at 40 • C/min and held for 1 min.
A weighted quadratic calibration model was used to calculate sample concentrations over the concentration range assayed (from 1 to 100 g/ml). This analytical method was based on the published guidelines [34] .
Determination of PK parameters
A non-compartmental analysis was employed in order to obtain the PK parameters using the PK solutions software version 2 (Summit Research Services, Mentrose, CO, USA). The half-life (t 1/2 ) was calculated as 0.693/ z where z is the terminal slope of the concentration-time curve. The area under the SPD concentration vs. time curve (AUC) was calculated using the trapezoidal rule and extrapolated to infinity. MRT (mean residence time) was calculated as AUMC/AUC, where AUMC is the area under the concentration-time product vs. time curve and extrapolated to infinity. Extravascular or oral clearance (CL/F) was calculated from the quotient Dose/AUC, F is the absolute bioavailability following i.p. administration. The apparent volume of distribution (V/F) or estimated volume of distribution was calculated as CL/F divided by the linear terminal slope. Vss/F was calculated as Dose times AUMC divided by AUC 2 .
Statistics
All data, except the electrophysiology experiments, are presented as mean ± s.e.m. (standard error of the mean). In the electrophysiology experiments, data are presented as mean ± s.d. (standard deviation). In all experiments, a p < 0.05 is considered significant. In the formalin test, data is presented as % control AUC ± s.e.m. in both the acute and inflammatory phases. ID 50 values in the formalin test (the dose reducing the nociception response by 50% compared to control) were determined by linear regression from individual experiments vs. each dose level converted to logarithmic scale. The different doses in each test were compared using ANOVA followed by a Tukey multiple comparison test. Comparison between ED 50 values was done using a t-test analysis. Dunnet's test was used to evaluate differences between baseline and treatment in the electrophysiological tests.
Results

SNL neuropathic pain model
All rats post-surgery displayed a significant reduction in pain threshold for the ipsilateral paw compared to pre-surgery: 1.5 ± 0.5, 1.5 ± 0.5, 1.4 ± 0.5 and 3.7 ± 1.1 for the MC, 40, 60, and 80 mg/kg groups respectively (Fig. 2 , p < 0.05). Contralateral paw had a pain threshold of >15 g in all groups which was similar to the tactile allodynia threshold before surgery (p > 0.05). A positive control, MTMCD, was used in the study as a comparator to SPD's antiallodynic activity. MTMCD is a VPA analogue previously reported to possess antiallodynic activity equipotent to gabapentin [35] . In this work, MTMCD at 80 mg/kg produced an antiallodynic effect significantly different than MC and 40 mg/kg SPD, but not 60 mg/kg or 80 mg/kg SPD. SPD had a dose-dependent antiallodynic effect 0.5-4 h after dosing (Fig. 2) . The TPE for antiallodynia for each experimental group was defined as the earliest time at which mean response threshold reached its highest value during the observation period. Both the 60 and 80 mg/kg significantly reduced tactile allodynia compared to control (p < 0.05 Fig. 2 ). The ED 50 calculated for SPD at TPE (60 min) was 49 mg/kg (95% CI of 9-61 mg/kg) which was equipotent to the ED 50 of gabapentin (32 mg/kg) and more than five times higher than the ED 50 of VPA (269 mg/kg) evaluated using the same paradigm [19, 36] .
Formalin test
The AUC for the formalin test, measured in both acute and chronic phases after 70 mg/kg SPD was significantly lower than control vehicle (p < 0.01) and showed a significant 55% and 74% Table. The table indicates the ratio of protected rats (not responding to the 15 g VFF denoted by the left number) to the total number of rats tested. The 60 min time point (highlighted) corresponding to SPD's time to peak antiallodynic effect. reduction in the acute and inflammatory phases respectively (Fig. 3) . Similar effects (46% and 75% reduction vs. control in the acute and inflammatory phases, respectively; p > 0.05 (Fig. 3) ) were only seen for VPA at a 300 mg/kg dose. Lower VPA doses were either unable to reduce the licking time significantly (70 mg/kg) or showed reduction in only one of the two phases evaluated (100 mg/kg) (Fig. 3) . The ID 50 values (the dose reducing the nociceptive response by 50% compared to control) for both SPD and VPA were calculated to be 39 and 40 mg/kg for SPD and 136 and 113 mg/kg for VPA, in the acute and inflammatory phases, respectively. SPD and VPA at their effective doses (70 mg/kg SPD, 300 mg/kg VPA) showed a similar percent reduction in nociception in the acute phase to be 23% and in the inflammatory phase to be 40% for both compounds. However SPD's effective dose was more than 4 times lower than VPA indicating an increased potency. Compared to the TD 50 values of the compounds previously mentioned [18] , the protective indices (PI) for SPD and VPA (calculated as the ratio between their ID 50 and TD 50 ) were 2.2 and 2.5, respectively. 
Carrageenan test
SPD produced a dose-dependent effect on carrageenan induced heat hyperalgesia at its TPE (Fig. 4) . Increasing doses of SPD caused a comparable increase in normalized mean withdrawal time, indicating that SPD was able to alleviate heat-induced hyperalgesia (Fig. 4) . Only the 70 mg/kg dose of SPD was statistically different from the Carr/MC group (negative control), whereas the 30, 50, and 70 mg/kg SPD doses were all statistically similar to Sal/MC (positive control). Compared to SPD, 100 mg/kg VPA was statistically different from Sal/MC but similar to Carr/MC, indicating that VPA at 100 mg/kg was not able to reduce heat hyperalgesia in the animals tested and was less potent than SPD. SPD's ED 50 value in the carrageenan model was 49 mg/kg (95% CI 29.3-110). The ipsilateral paw was significantly thicker than the contralateral paw (p < 0.05) one hour after testing, confirming carrageenan induced inflammation in all carrageenan injected groups but not in the Sal/MC group (Fig. 5A) . Neither SPD nor VPA decreased paw thickness an hour following administration (Fig. 5A) .
Paw edema evaluation
70 mg/kg SPD, the highest dose evaluated in this work, was evaluated for its effect on carrageenan induced paw edema vs. 100 mg/kg Ibuprofen as a positive control (Fig. 5B) up to 24 h post carrageenan injection, similar to a previously published paradigm [28] . Plantar injection of carrageenan significantly increased paw thickness compared to injection of saline up to 72 h post injection (data not shown). SPD did not decrease percent paw thickness up to 24 h following carrageenan injection (Fig. 5B) . Ibuprofen decreased percent paw thickness, which was significant after 4 h (p < 0.05). Plantar injection of saline did not produce edema, as witnessed by a statistically similar percent paw thickness over time.
Acetic acid induced abdominal constriction test (writhing) test
The mean number of writhes was significantly reduced after 30, 50, and 70 mg/kg doses of SPD (p < 0.001) (Fig. 6A) . VPA significantly reduced the number of writhes at doses of 50 and 100 mg/kg (Fig. 6B) . The control groups in both experiments had a similar mean number of writhes (43 ± 5.3 and 48 ± 4.0 for the SPD control and VPA control respectively). SPD and VPA showed similar dose response curves (Fig. 6) and potency in this model with ED 50 values of 40 mg/kg (95% CI 24.3-67 mg/kg) and 44 mg/kg (95% CI 18-61 mg/kg) for SPD and VPA, respectively. Due to its higher TD 50 , VPA had a higher PI at 8.8 vs. 2.2 for SPD.
Electrophysiology recordings
A characteristic CAP response in the low and high frequency protocols is shown in Fig. 7 . In the tonic stimulation protocol, the peak-to-peak area ratio (PAR) of both A and C fibers (determined based on their conduction velocities) was constant during baseline recording. Vehicle perfusion (ACSF with 1% ethanol) did not produce any significant effect on CAPs recorded (data not shown). Following perfusion with 1 or 3 mM SPD, no significant difference was seen in the normalized PAR value compared to baseline record- ings of CAPs in both the A and C fibers. In contrast, perfusion with 1 mM lidocaine (after a 15 min SPD washout period) significantly decreased the PAR value of both A and C fibers (Fig. 8A) . In the phasic stimulation protocol, CAPs were recorded following high frequency stimulation (40 Hz) producing 28 CAPs per epoch. The ratio between last and first CAP ( f) following perfusion with the highest concentration of SPD, 3 mM, were similar to baseline (96.5% vs. 96% for baseline and 3 mM SPD respectively, Fig. 8B ). However, following administration of 1 mM lidocaine, f values were significantly decreased (38.5% for lidocaine p < 0.001). 3 mM SPD did not decrease PAR of the first and last CAP (100% vs. 90% for the first and last CAP following baseline and 3 mM SPD respectively, Fig. 8B ). Following perfusion with lidocaine, a significant decrease in both the first and last CAP was observed (100% vs. 22.5% in the first CAP and 100% vs. 14.7% for the last CAP of baseline and lidocaine, respectively, Fig. 8B ).
PK results and PK-PD correlation
The plasma concentration vs. time curve following i.p. administration of 80 mg/kg SPD is depicted in Fig. 9 . SPD's peak plasma concentration (C max ) was 77.2 mg/L in mice and 66.2 mg/L in rats. C max was observed 15 min following administration in both species. PK parameters were estimated utilizing a non-compartmental approach. In mice and rats, SPD had the following PK parameters respectively: t 1/2 (half-life) of 19 min (0.3 h) and 47 min (0.8 h), CL/F 1.7 l/h/kg and 0.9 l/h/kg, volume of distribution 0.9 l/kg and 1.1 l/kg (Fig. 9 ). SPD's t max was 15 min as determined by its time to peak effect in the behavioral testing, and in previous anticonvulsant screening tests [18] .
Discussion
Accumulating evidence has indicated that the cellular changes which occur in injured nociceptors following injury are not solely responsible for the chronic pain state. Inflammatory mediators released from neurons and glia alter neuronal function in both the peripheral and central nervous system, and both are thought to contribute to the development of a chronic pain state following tissue injury [10] . This suggests that compounds proposed for use in chronic pain should possess activity in both the neuropathic and inflammatory pain models. SPD is a novel amide derivative of VPA, developed in an attempt to design a better and more tolerable CNS drug that will be a second generation compound to VPA. SPD previously showed the highest potency (out of thirty four novel compounds) and a broad spectrum profile in numerous animal seizure models and was active in two benzodiazepine-resistant models for status epilepticus [18, 19] . Epilepsy and neuropathic pain share similar underlying mechanism of action [11] and some AEDs (e.g. gabapentin, pregabalin) are regarded as the mainstay of neuropathic pain treatment [38, 39] . With this in mind, we assessed SPD's antinociceptive activity in both the neuropathic and acute inflammatory pain models presented in this study and compared them to the activity of SPD's parent compound VPA. a Taken from [37] parameters derived following administration of 50 mg/kg VPA orally (p.o.) to mice.
b Taken from [36] following administration of 300 mg/kg VPA i.p. to rats.
SPD is potent and effective in multiple pain models
SPD's ED 50 in the SNL model was initially estimated in a previous work [19] . In this work, we report the complete dose response in the SNL model. We find that SPD has five times higher potency than VPA and is equipotent to gabapentin. Compared to VPA, SPD also showed increased potency in the formalin and carrageenan models. In the formalin test, anti-inflammatory drugs such as the NSAIDs indomethacin and naproxen, have been shown to exert their effect only in the second phase [24, 26] . In contrast, centrally acting drugs, including morphine, codeine, and orphenadrine, exert their effect on both phases of the test [24] . VPA and SPD were found to be active in both phases of the test, similar to centrally acting drugs, distinguishing them from conventional antiinflammatory drugs. SPD had no effect on carrageenan induced paw edema at the highest dose tested, unlike the NSAID ibuprofen and previous reports for indomethacin [40] . These further suggest a different anti-nociceptive profile for SPD compared to marketed NSAIDs. Moreover, SPD's potency in the formalin test is lower (70 mg/kg) than morphine (5-10 mg/kg) but comparable to codeine (25-50 mg/kg) evaluated in the same test [24] .
We used the writhing test as a useful model for visceral pain [41, 42] . Visceral pain has different clinical features from that of somatic pain [43] , which might explain why some CNS drugs (e.g. topiramate) exert their effect in the animal writhing test and not in the formalin test [44, 45] . We evaluated SPD's potential in this test and observed a maximum efficacy at a dose of 30 mg/kg. VPA was active in the writhing test at lower doses than those seen in the other pain models, suggesting a possibly different mode of action, and validating the use of this test in addition to the other models. In contrast to the SNL, formalin, and carrageenan models, VPA and SPD were equipotent in the writhing test, as indicated by their identical ED 50 values. It is possible that SPD saturates an active site (yet to be determined) responsible for the effect which was not seen in the formalin and carrageenan tests. However, VPA's higher TD 50 makes its PI value higher compared to SPD in this test. The ED 50 of both SPD and VPA are either better or comparable to the commercially available NSAIDs evaluated in this model (e.g. aspirin -82-228 mg/kg, naproxen -13 mg/kg, ibuprofen -33 mg/kg, piroxicam -100 mg/kg [46, 47] ). On the contrary SPD's potency in the writhing test was lower than morphine [48] .
Possible mechanisms of action
In order to gain an insight into SPD's mechanism of action, we investigated whether SPD's anti-nociceptive effect is associated with modulation of peripheral neuronal activity. Lidocaine, a local anesthetic blocker of voltage dependent sodium channels, modifies CAPs in peripheral nerves [49, 50] and was used as a positive control in this study [51] [52] [53] . Unlike lidocaine, SPD (up to 3 mM) did not produce a significant change in conduction properties after either tonic or phasic stimulation. This concentration was six fold higher than SPD's C max at the highest effective dose in-vivo (80 mg/kg). Thus SPD is not likely to act on peripheral voltagedependent sodium channels. A possible beneficial correlate is that SPD may not suffer from adverse side effects such as vertigo, somnolence, and nausea associated with membrane stabilizing drugs [11] , but this remains to be determined. NSAIDs, although shown to suppress conduction properties in the CAP model, have not been useful for the treatment of chronic neuropathic pain and also suffer from long term side effects such as gastrointestinal bleeding. Since SPD is not a membrane stabilizing drug and does not act as an anti-inflammatory agent per se, we conclude that SPD likely exerts its effect through a combination of mechanisms that are yet to be fully defined. A previous study evaluated SPD's mechanism of action in-vitro in primary cultures of dissociated cortical neurons to indicate that SPD enhanced GABA induced currents [54] . Although some clinically used drugs, e.g. benzodiazepines, were shown to have antinociceptive effects in animals and humans, possibly due to their effect on GABA receptors [55] , it is still unknown whether SPD's antinociceptive properties described herein are attributed to its potential GABAergic mechanism of action.
Pharmacokinetics
In the PK study, SPD's t max was identical to its TPE in the behavioral tests and in previously reported anticonvulsant tests [18] . This suggests rapid distribution to all body compartments following i.p. administration. The high dose given, 80 mg/kg, was not associated with any signs of toxicity except sedation in both species for the first 15 min after dosing, which was not expected to affect SPD's PK. SPD's t 1/2 in rats (0.8 h) is similar to the t 1/2 previously reported for SPD using a lower dose (60 mg/kg, t1/2 = 0.84 h) [18] . In contrast, both the CL/F and Vss/F were half of what was reported in the previous study (0.9 vs. 1.9 for CL/F and 1.1 vs. 2.3 for Vss/F). Since both these PK parameters are dependent on bioavailability when given extra-vascularly, this two-fold reduction might be explained by different bioavailability (F) due to the different parenteral vehicles (MC suspension in the current study vs. a multisol solution in the previous study) which can affect SPD's absolute bioavailability (F).
Compared to VPA, SPD has a shorter t 1/2 and a higher CL/F values in mice [36, 37, 56] . Both SPD and VPA have been shown to be primarily eliminated by metabolism, thereby indicating that the higher CL/F value for SPD is due to higher affinity to liver enzymes. Since t 1/2 is directly proportional to V and inversely proportional to CL, this indicates that SPD's shorter half-life is governed mainly by increased metabolic (hepatic) clearance. In humans, drugs with shorter half-lives can reach plasma steady state levels quicker thereby making those good candidates for emergency or acute care use. However, it is known that a drug's half-life in rodents is shorter than in humans (the smaller the animal, the shorter the half life) [57] , therefore one may expect a longer half-life for SPD in humans, like in the case of SPD's eight carbon homologue VCD [58] .
Conclusion
The novel VPA amide derivative, SPD, was active in three animal models for acute inflammatory pain as well as in chronic neuropathic pain, and in most tests was more potent than VPA. Moreover, its rapid PK may enable it to be used in acute care. Although SPD's mechanism of action remains to be elucidated, the results of this study support the hypothesis that SPD does not directly modulate neuronal conduction properties, and is not an anti-inflammatory agent per se. Further pharmacological studies to ascertain SPD's novel pharmacological profile, and potential as a future analgesic and anti-seizure drug are warranted. 
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